Australia Markets open in 5 hrs 3 mins

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1933+0.0165 (+9.33%)
As of 02:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.1768
Open0.1795
Bid0.1922 x 900
Ask0.1950 x 1000
Day's range0.1759 - 0.2000
52-week range0.1300 - 1.6700
Volume730,583
Avg. volume781,228
Market cap15.427M
Beta (5Y monthly)0.38
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

    REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL. The presentation will be available on-demand beginning at 7 AM Eastern

  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

    REDWOOD CITY, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2022. First Quarter 2022 and Recent Corporate Highlights Continuing dialogue with the U.S. Food and Drug Administration (FDA) to obtain alignment on the design of a study to provid

  • GlobeNewswire

    Soleno Therapeutics Announces Presentation of Long-Term Hyperphagia and Behavioral Data in Patients Receiving DCCR for Treatment of Prader-Willi Syndrome

    Results Show Significant Improvements in Hyperphagia and PWS-Related Behaviors in DCCR-Treated Patients Presentations at the Pediatric Academic Societies 2022 Virtual Annual Meeting and Pediatric Endocrinology Society 2022 Virtual Annual Meeting REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced two presentations hig